What Regeneron's latest 10-Q says: 5 signals

Regeneron filed its latest 10-Q with the SEC on Jul 30, 2026. It discusses cash flow concern, governance change and international growth.

Public (REGN)Biotechnology Research10,000+ employeesregeneron.comLinkedIn

Filed: Jul 30, 2026
Filings: 2
Signals: 14

10-Q · latest 10

What Regeneron's 10-Q filings say

10-Q
Filed Jul 30, 2026 · 5 signals
SEC EDGAR
- Litigation materialNegative
  Regeneron faces new class action lawsuit for alleged securities law violations in July 2026.
  A new putative class action complaint was filed against the company and certain employees, creating potential for substantial legal costs, management distraction, and a need for e-discovery and litigation support services.
- RestructuringNeutral
  Regeneron is phasing out its staggered board structure, with annual elections for all directors by 2028.
  This corporate governance restructuring, approved by shareholders in 2025, increases board accountability and could make leadership more receptive to new initiatives that drive efficiency, cost savings, or strategic value to boost shareholder confidence.
- International growthPositive
  Regeneron signals increasing revenue focus on international markets.
  The company expects revenue from outside the United States to increase as its products gain approval in new jurisdictions, highlighting exposure to currencies in Japan, Europe, Canada, China, and Australia.
- Cash flow concernNegative
  Regeneron's $2.7B debt load poses risk to cash flow for R&D and M&A initiatives.
  With $2.707 billion in outstanding debt, management warns that a substantial portion of cash flow may be required for debt service, reducing availability for other strategic purposes like business development, research, and acquisitions.
  $2.7B
  outstanding indebtedness
10-Q
Filed Apr 29, 2026 · 9 signals
SEC EDGAR
- Capex increasePositive
  Regeneron investing $255.8M in Q1 for facility expansion in US and Ireland
  The company is undergoing significant construction and expansion of its facilities.
  $255.8M
  Capital expenditures for facility construction and expansion
- Acquisition announcedPositive
  Regeneron boosts M&A activity with $101.9M spent on in-process R&D in Q1 2026
  The company dramatically increased spending on acquiring external research assets, from $12.3M to $101.9M year-over-year.
  $101.9M
  Acquired in-process research and development expense for the three months ended March 31, 2026.
- Capex increasePositive
  Regeneron boosts R&D spend by $216M YoY, increasing headcount
  R&D expenses grew to $1.54 billion in Q1, driven by higher clinical trial costs and hiring more R&D staff.
  $1.5B
  Quarterly research and development expense
- Data investmentNeutral
  Acquired R&D spending surges 8x to $101.9M, signaling new data integration needs.
  $101.9M
  Acquired in-process research and development expense for Q1 2026
- Capex increasePositive
  Regeneron spends $101.9M in Q1 to acquire new antibody technology
  The company is actively acquiring external innovation, spending over $100M on in-process R&D from another biotech firm.
  $101.9M
  Acquired in-process research and development (IPR&D)
  antibody
- Litigation materialNegative
  Regeneron facing securities class action lawsuit diverting management resources
  The company is defending a class action lawsuit filed in Jan 2025, which it states could result in substantial costs and divert management attention.

Showing 10 of 14 filing signals. The Signal API returns all of them.

Get them with one API call

Earnings calls

Regeneron earnings headlines

From earnings call transcripts (Signal API type earnings-transcripts).

Earnings call headlines
Call date	Period	What the company said
Oct 28, 2025	Q3 FY2025	Announces $7+ billion investment in new manufacturing infrastructureTo mitigate supply chain risks and bolster national security, the company is investing over $7 billion in new infrastructure and manufacturing facilities. This massive capital expenditure signals a long-term, large-scale project requiring partners in construction, engineering, manufacturing equipment, and operational technology.
Oct 28, 2025	Q3 FY2025	Announced $7B+ investment in manufacturing and infrastructureThe company is making a multi-year, multi-billion dollar investment in new infrastructure and manufacturing facilities, indicating significant budget for construction, equipment, and related operational technology.
Oct 28, 2025	Q3 FY2025	FDA rejects drug application due to third-party manufacturing issuesThe FDA issued a Complete Response Letter for a key product (EYLEA HD prefilled syringe) due to unresolved inspection findings at their contract manufacturer, Catalent. This creates significant pressure to secure reliable manufacturing partners and improve supply chain oversight, opening opportunities for quality management, compliance, and manufacturing tech vendors.
Oct 28, 2025	Q3 FY2025	Patient assistance fund matching program fails to gain tractionA $200 million matching program for a patient assistance fund has failed, raising less than $1 million in the quarter due to a lack of external donations. The CEO expressed disappointment, indicating a pain point around managing drug affordability and a need for new strategies or partners for patient access solutions.
Oct 28, 2025	Q3 FY2025	Expanding siRNA portfolio for complex diseases like Alzheimer'sThe company is advancing its siRNA portfolio into clinical trials for complex neurological diseases like Parkinson's and Alzheimer's. This type of research is data-intensive and often leverages AI/ML for target identification and trial analysis, suggesting budget for advanced analytics and computational biology tools.
Oct 28, 2025	Q3 FY2025	Advancing siRNA pipeline through key collaboration with AlnylamThe company highlighted its growing siRNA portfolio, which is a direct result of its research collaboration with Alnylam. This partnership is critical to their strategy in neurology and metabolic diseases, indicating a reliance on external innovation and creating potential opportunities for other biotech partners or service providers in the RNAi space.

Signal API · MCP

Track Regeneron with the Signal API

One POST /v1/companies/enrich call with regeneron.com returns Regeneron 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.

Start Free1,000 free creditsUse it in Claude via MCP

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"regeneron.com","signal_types":["sec-10q"],"limit":20}'

Same industry

Questions about Regeneron 10-Q

When did Regeneron file its latest 10-Q?

Regeneron filed its latest 10-Q on Jul 30, 2026. The one before it was filed on Apr 29, 2026.

What did Regeneron disclose in its latest 10-Q?

From the filing dated Jul 30, 2026: Regeneron faces new class action lawsuit for alleged securities law violations in July 2026.

What did Regeneron say on its recent earnings calls?

Q3 FY2025: Announces $7+ billion investment in new manufacturing infrastructure (dated Oct 28, 2025).

Where can I read Regeneron's 10-Q filing?

The full filing is on SEC EDGAR: https://www.sec.gov/Archives/edgar/data/872589/000087258926000025/regn-20260630.htm. This page summarizes what the filing says and links to it.

Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.

Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.

Data as of Sep 30, 2026.

How this data is built →Get it from the Signal API →

What Regeneron's latest 10-Q says: 5 signals

What Regeneron's 10-Q filings say

Regeneron earnings headlines

Track Regeneron with the Signal API

10-Q at related companies

Questions about Regeneron 10-Q